Technology
Health
Biotechnology

Vermillion

$1.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.74%) Today
-$0.01 (-0.74%) Today

Why Robinhood?

You can buy or sell Vermillion and other stocks, options, ETFs, and crypto commission-free!

About

Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Read More The company's bio-analytical solutions helps physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion was founded on December 9, 1993 and is headquartered in Austin, TX.

Employees
39
Headquarters
Austin, Texas
Founded
1993
Market Cap
102.52M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
152.33K
High Today
$1.39
Low Today
$1.32
Open Price
$1.34
Volume
28.98K
52 Week High
$1.45
52 Week Low
$0.2701

Collections

Technology
Health
Biotechnology
Medical
US
North America
Female CEOs

News

Yahoo FinanceMar 12

Vermillion to Report Fourth Quarter and Year End 2018 Financial Results on Thursday, March 28

AUSTIN, Texas, March 12, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the fourth quarter and year ended December 31, 2018 on Thursday, March 28, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Thursday, March 28 th @ 4:30pm Eastern Time Domestic: 877-407-4018 International: 201-689-8471 Conference ID: 13688624 Webcast: http://public.vi...

88
MarketBeatMar 6

Stock Price, News, & Analysis for Vermillion

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovaria...

25

Earnings

-$0.06
-$0.05
-$0.05
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Available Mar 28, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.